Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press138910.17650/1994-4098-2025-21-4-53-62MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИReview ArticleInterval breast cancer: current state of the problemИнтервальный рак молочной железы: современное состояние проблемыhttps://orcid.org/0000-0002-4682-18111066-9708KayukovaElena V.КаюковаЕлена Владимировна
Russian Federation
elena_pochta22@mail.ruGorbachevaO. N.ГорбачеваОльга Николаевна
Russian Federation
elena_pochta22@mail.ruChita State Medical Academy, Ministry of Health of RussiaФГБОУ ВО «Читинская государственная медицинская академия» Минздрава РоссииTrans-Baikal Regional Oncology CenterГУЗ «Забайкальский краевой онкологический диспансер»20012026214536227082025Copyright ©; 2026, Kayukova E.V., Gorbacheva O.N.Copyright ©; 2026, Каюкова Е.В., Горбачева О.Н.2026Kayukova E.V., Gorbacheva O.N.Каюкова Е.В., Горбачева О.Н.https://creativecommons.org/licenses/by/4.0https://ojrs.abvpress.ru/ojrs/article/view/1389

Breast cancer is a screenable disease. The purpose of screening is to improve the detection of breast cancer at early stages and reduce mortality from this pathology. One of the problems of screening is the possibility of diagnosing cancer in the interscreening period, which is defined as interval breast cancer (iBC). A review of the literature on this topic for the last 10 years is performed. Epidemiological data on iBC in the world are presented, a modern radiological classification, clinical, biological, and radiological features of iBC are indicated. Factors that increase the risk of detecting iBC are presented: age, interscreening interval, mammographic density, intake of hormonal drugs, aggravated personal and family oncological history, genetic rearrangements. Currently known prognostic models for the development of iBC are indicated. The world experience in the prevention of iBC development is summarized, including optimization of screening intervals, the use of additional or alternative methods of visualization of mammary gland pathology, the use of artificial intelligence technologies, and hormone prophylaxis.

Рак молочной железы является скринируемым заболеванием. Скрининг позволяет улучшить его выявляемость на ранних стадиях, снизить смертность от этой патологии. Одной из проблем скрининга является возможность диагностики рака в межскрининговый период, что определяется как интервальный рак молочной железы (иРМЖ). В статье выполнен обзор литературы по данной теме за последние 10 лет. Приведены эпидемиологические данные по иРМЖ в мире, указаны современная рентгенологическая классификация, клинико-биологические, рентгенологические особенности иРМЖ. Представлены факторы, увеличивающие риск выявления иРМЖ: возраст, межскрининговый интервал, маммографическая плотность, прием гормональных препаратов, отягощенный онкологический личный и семейный анамнез, генетические перестройки. Указаны известные в настоящее время прогностические модели развития иРМЖ. Обобщен мировой опыт профилактики развития иРМЖ, включающий оптимизацию интервалов скрининга, использование дополнительных или альтернативных методик визуализации патологии молочных желез, применение технологий искусственного интеллекта, гормонопрофилактику.

interval breast cancerscreeningprognosispreventionoccult breast cancermissed breast cancerинтервальный рак молочной железыскринингпрогнозированиепрофилактикаоккультный рак молочной железыпропущенный рак молочной железыИсследование проведено без спонсорской поддержки.Ren W., Chen M., Qiao Y., Zhao F. Global guidelines for breast cancer screening: a systematic review. Breast 2022;64:85–99. DOI: 10.1016/j.breast.2022.04.003Zhang Y., Rodriguez J., Mao X. et al. Incidence and risk factors of interval and screen-detected breast cancer. JAMA Oncol 2025;11(5):519–27. DOI: 10.1001/jamaoncol.2025.0167Mills C., Sud A., Everall A. et al. Genetic landscape of interval and screen detected breast cancer. NPJ Precis Onc 2024;8:122. DOI: 10.1038/s41698-024-00618-6Houssami N., Hunter K. The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. NPJ Breast Cancer 2017;3:12. DOI: 10.1038/s41523-017-0014-xGoh R.S.J., Chong B., Yeo S. et al. Current strategies to reducing interval breast cancers: a systematic review. Breast Cancer (Dove Med Press) 2025;17:531–44. DOI: 10.2147/BCTT.S532884Yu T.T., Hoyt A.C., Joines M.M. et al. Mammographic classification of interval breast cancers and artificial intelligence performance. J Natl Cancer Inst 2025;117(8):1627–38. DOI: 10.1093/jnci/djaf103Shetat O.M.M., Abdelaal M.M.A., Hussein D. et al. Interval breast cancer: radiological surveillance in screening Egyptian population. Egypt J Radiol Nucl Med 2024;55(20). DOI: 10.1186/s43055-024-01193-3Yeom Y.K., Chae E.Y., Kim H.H. et al. Screening mammography for second breast cancers in women with history of early-stage breast cancer: factors and causes associated with non-detection. BMC Med Imaging 2019;19(1):2. DOI: 10.1186/s12880-018-0303-3Mann R.M., Athanasiou A., Baltzer P.A. et al. Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol 2022;32(6):4036–45.Ofri A., Moore K. Occult breast cancer: where are we at? Breast 2020;54:211–5. DOI: 10.1016/j.breast.2020.10.012Meshkat B., Prichard R.S., Al-Hilli Z. et al. A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer. Breast 2015;24(3):278–82. DOI: 10.1016/j.breast.2015.02.032Knox M., O’Brien A., Szabó E. et al. Impact of full field digital mammography on the classification and mammographic characteristics of interval breast cancers. Eur J Radiol 2015;84(6):1056–61. DOI: 10.1016/j.ejrad.2015.03.007Lowery J.T., Byers T., Hokanson J.E. et al. Complementary approaches to assessing risk factors for interval breast cancer. Cancer Causes Control 2011;22(1):23–31. DOI: 10.1007/s10552-010-9663-xKou K., Cameron J., Youl P. et al. Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study. Breast Cancer 2023;30(3):466–77. DOI: 10.1007/s12282-023-01439-4Blanch J., Sala M., Ibáñez J. et al. INCA Study Group. Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme. PLoS One 2014;9(10):e110207. DOI: 10.1371/journal.pone.0110207Gerstung M., Jolly C., Leshchiner I. et al. The evolutionary history of 2,658 cancers. Erratum in: Nature 2023;614(7948):E42. DOI: 10.1038/s41586-022-05601-4Rodriguez J., Grassmann F., Xiao Q. et al. Investigation of genetic alterations associated with interval breast cancer. JAMA Oncol 2024;10(3):372–9. DOI: 10.1001/jamaoncol.2023.6287Grassmann F., He W., Eriksson M. et al. Interval breast cancer is associated with other types of tumors. Nat Commun 2019;10(1):4648. DOI: 10.1038/s41467-019-12652-1Sala M., Domingo L., Louro J. et al. Survival and disease-free survival by breast density and phenotype in interval breast cancers. Cancer Epidemiol Biomarkers Prev 2018;27(8):908–16. DOI: 10.1158/1055-9965.EPI-17-0995Ten Velde D.E., Duijm L.E.M., van der Sangen M.J.C. et al. Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme. Br J Cancer 2024;130(9):1561–70. DOI: 10.1038/s41416-024-02633-7Kerlikowske K., Scott C.G., Mahmoudzadeh A.P. et al. Automated and clinical breast imaging reporting and data system density measures predict risk for screen-detected and interval cancers: a case-control study. Ann Intern Med 2018;168(11):757–65. DOI: 10.7326/M17-3008Dreher N., Matthys M., Hadeler E. et al. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer. Breast Cancer Res Treat 2022;191(3):623–9. DOI: 10.1007/s10549-021-06451-wNoguchi N., Teixeira-Pinto A., Marinovich M.L. et al. Risk models to predict screen-detected and interval breast cancers in population mammography screening participants. Cancers (Basel) 2025;17(5):810. DOI: 10.3390/cancers17050810Kushunina D.V., Kalinina A.M., Drozdova L.Yu. Breast cancer screening: regional practices. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine 2019;22(4):37–42. (In Russ.). DOI: 10.17116/profmed20192204137Кушунина Д.В., Калинина А.М., Дроздова Л.Ю. Выявление рака молочной железы в рамках диспансеризации: практика регионов. Профилактическая медицина 2019;22(4):37–42. DOI: 10.17116/profmed20192204137Lomakov S.Yu. Volumes of mammographic studies in modern conditions of providing preventive measures. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine 2020;23(4):41–4. (In Russ.). DOI: 10.17116/profmed20202304141Ломаков С.Ю. Объемы маммографических исследований в современных условиях проведения профилактических мероприятий. Профилактическая медицина 2020;23(4):41–4. DOI: 10.17116/profmed20202304141Hunt K.A., Rosen E.L., Sickles E.A. Outcome analysis for women undergoing annual versus biennial screening mammography: a review of 24,211 examinations. AJR Am J Roentgenol 1999;173(2):285–9. DOI: 10.2214/ajr.173.2.10430120Moorman S.E.H., Pujara A.C., Sakala M.D. et al. Annual screening mammography associated with lower stage breast cancer compared with biennial screening. AJR Am J Roentgenol 2021;217(1):40–7. DOI: 10.2214/AJR.20.23467Alabousi A., Patlas M.N. Annual mammographic screening reduces the risk of interval or higher stage invasive breast cancers: lessons for today and tomorrow. Can Assoc Radiol J 2022;73(3):446, 447. DOI: 10.1177/08465371211070555Glechner A., Wagner G., Mitus J.W. et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev 2023;3(3):CD009632. DOI: 10.1002/14651858.CD009632.pub3Libesman S., Li T., Marinovich M.L. et al. Interval breast cancer rates for tomosynthesis vs mammography population screening: a systematic review and meta-analysis of prospective studies. Eur Radiol 2025;35(3):1478–89. DOI: 10.1007/s00330-024-11085-9Nissan N., Comstock C.E., Sevilimedu V. et al. Diagnostic accuracy of screening contrast-enhanced mammography for women with extremely dense breasts at increased risk of breast cancer. Radiology 2024;313(1):e232580. DOI: 10.1148/radiol.232580Berg W.A., Zhang Z., Lehrer D. et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012;307(13):1394–404. DOI: 10.1001/jama.2012.388Díaz O., Rodríguez-Ruíz A., Sechopoulos I. Artificial Intelligence for breast cancer detection: technology, challenges, and prospects. Eur J Radiol 2024;175:111457. DOI: 10.1016/j.ejrad.2024.111457Woo O.H., Song S.E., Choe S.J. et al. Invasive breast cancers missed by AI screening of mammograms. Radiology 2025;315(3):e242408. DOI: 10.1148/radiol.242408Kim H.J., Kim H.H., Kim K.H. et al. Mammographically occult breast cancers detected with AI-based diagnosis supporting software: clinical and histopathologic characteristics. Insights Imaging 2022;13(1):57. DOI: 10.1186/s13244-022-01183-xEriksson M., Czene K., Conant E.F., Hall P. Use of low-dose tamoxifen to increase mammographic screening sensitivity in premenopausal women. Cancers (Basel) 2021;13(2):302. DOI: 10.3390/cancers13020302Dileep G., Gianchandani Gyani S.G. Artificial intelligence in breast cancer screening and diagnosis. Cureus 2025;14(10):e30318. DOI: 10.7759/cureus.30318Zaridze D.G. Prospects of using artificial intelligence for improving cancer screening efficacy. Obshchestvennoe zdorovye = Public Health 2024;4(4):24–42. (In Russ.). DOI: 10.21045/2782-1676-2024-4-4-24-42Заридзе Д.Г. Перспективы применения искусственного интеллекта для повышения эффективности cкрининга злокачественных новообразований. Общественное здоровье 2024;4(4):24–42. DOI: 10.21045/2782-1676-2024-4-4-24-42Chang Y.W., An J.K., Choi N. et al. artificial intelligence for breast cancer screening in mammography (AI-STREAM): a prospective multicenter study design in Korea using AI-Based CADe/x. J Breast Cancer 2022;25(1):57–68. DOI: 10.4048/jbc.2022.25.e4Kühl J., Elhakim M.T., Stougaard S.W. et al. Population-wide evaluation of artificial intelligence and radiologist assessment of screening mammograms. Eur Radiol 2024;34(6):3935–46. DOI: 10.1007/s00330-023-10423-7